These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19042019)

  • 21. Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
    Kamo N; Naomoto Y; Shirakawa Y; Yamatsuji T; Hirota S; Fujiwara Y; Noma K; Sakurama K; Takaoka M; Nagatsuka H; Gunduz M; Matsuoka J; Tanaka N
    Hum Pathol; 2009 Nov; 40(11):1643-9. PubMed ID: 19695682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia.
    Chen CC; Gau JP; You JY; Lee KD; Yu YB; Lu CH; Lin JT; Lan C; Lo WH; Liu JM; Yang CF
    Am J Hematol; 2009 Feb; 84(2):87-92. PubMed ID: 19127593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CXCR4 is a prognostic marker in acute myelogenous leukemia.
    Spoo AC; Lübbert M; Wierda WG; Burger JA
    Blood; 2007 Jan; 109(2):786-91. PubMed ID: 16888090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia.
    Ayala RM; Martínez-López J; Albízua E; Diez A; Gilsanz F
    Am J Hematol; 2009 Feb; 84(2):79-86. PubMed ID: 19097174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
    Theocharis SE; Klijanienko JT; Padoy E; Athanassiou S; Sastre-Garau XX
    Med Sci Monit; 2009 Aug; 15(8):BR221-6. PubMed ID: 19644410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FAK expression regulation and therapeutic potential.
    Li S; Hua ZC
    Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
    Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
    Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.
    Wagner PL; Hyjek E; Vazquez MF; Meherally D; Liu YF; Chadwick PA; Rengifo T; Sica GL; Port JL; Lee PC; Paul S; Altorki NK; Saqi A
    J Thorac Cardiovasc Surg; 2009 Mar; 137(3):615-21. PubMed ID: 19258077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
    Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.
    Oelschlaegel U; Mohr B; Schaich M; Schäkel U; Kroschinsky F; Illmer T; Ehninger G; Thiede C
    Cytometry B Clin Cytom; 2009 Sep; 76(5):321-7. PubMed ID: 19291801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
    Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
    Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia.
    Nückel H; Switala M; Collins CH; Sellmann L; Grosse-Wilde H; Dührsen U; Rebmann V
    Clin Immunol; 2009 Jun; 131(3):472-80. PubMed ID: 19318232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.
    Chamuleau ME; van de Loosdrecht AA; Hess CJ; Janssen JJ; Zevenbergen A; Delwel R; Valk PJ; Löwenberg B; Ossenkoppele GJ
    Haematologica; 2008 Dec; 93(12):1894-8. PubMed ID: 19050070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia.
    Al-Mawali A; To LB; Gillis D; Hissaria P; Mundy J; Lewis I
    Int J Lab Hematol; 2009 Feb; 31(1):61-8. PubMed ID: 19143870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
    Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
    Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.